Monday, April 23, 2018 6:18:33 PM
https://technical420.com/cannabis-article/5-canadian-cannabis-stocks-investors-need-watch-week
EVIO: Announces a Major Milestone
As new legal marijuana markets continue to open and existing markets continue to mature, demand for testing services continues to increase. This is a trend we expect to become more prominent over the coming quarters and have been closely monitoring this opportunity.
One of the companies capitalizing on this emerging opportunity is EVIO, Inc. (EVIO) and we are bullish on the company’s leverage to North American market. From California to Canada, recreational marijuana has become a major topic and EVIO is capitalizing on both of these burgeoning markets.
On Friday, EVIO received a favorable response from the market after announcing the establishment of a new wholly-owned subsidiary, EVIO Canada, to serve as the parent company for the company’s Canadian operations.
Concurrently, EVIO Canada entered a binding agreement to acquire 50% of Keystone Labs Inc., a privately-held, independent contract-testing laboratory specializing in quality testing for regulated industries located in Edmonton, Alberta. Founded in 2005, Keystone Labs provides a full array of high quality analytical and microbiological analyses to pharmaceutical, biotechnological, medical device and natural health product industries according to Good Manufacturing Practices (GMP). We are bullish on this acquisition which is expected to close on or about May 1st.
From a valuation and execution standpoint, we find EVIO to be an attractive opportunity and investors need to monitor this cannabis stock. As the marijuana testing company continues to execute, fundamentals will continue to improve, and we think the market is significantly under-appreciating this opportunity.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM